Tumor and genetic features that separate platinum‑resistant ovarian cancer patients from those progression‑free at five years

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Using the CONSORE database, the ORTRAI cohort was assembled at Centre Jean Perrin to compare patients who progressed on first‑line platinum therapy with those progression‑free five years after treatment. Clinical records, biological data, and tumor histology will be collected and compared with literature cohorts to confirm representativeness. Immunohistochemistry and molecular analyses will be performed on available FFPE tumor blocks to identify distinguishing genomic and tissue features. Integrative analysis will seek markers associated with platinum resistance or long‑term durable response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.
* Corresponding to one of the two groups below:

  * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
  * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
* Affiliation to a social security scheme
* Patient who signed the genetic consent form

Exclusion Criteria:

* Minor patient
* Pregnant patient
* Patient under guardianship or conservatorship
* Patients who object to the collection of their medical/paramedical data
* Patient for whom the center does not have biological material for genomic analysis (FFPE block)
* Patient under administrative, judicial decision or AME (State Medical Aid)

Where it's running

• Centre Jean Perrin
  Clermont-Ferrand, Puy de Dome, France Recruiting

Study contacts

• Principal investigator: Tressie HERRMANN, MD — Centre Jean Perrin
• Study coordinator: Judith PASSILDAS JAHANMOHAN, PhD
• Email: judith.passildas@clermont.unicancer.fr
• Phone: 0463663337

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• EHR-based approach to boost HBOC genetic testing in at-risk women

  A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.

  Recruiting Columbia University · New York, New York · NCT07876349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.